Mary Caire v. Genetic Direction LLC
Opinion
AFFIRMED; Opinion Filed April 2, 2020
In the
Court of Appeals
Fifth District of Texas at Dallas No. 05-19-00151-CV
MARY CAIRE, Appellant
V.
GENETIC DIRECTION LLC, Appellee
On Appeal from the 134th Judicial District Court Dallas County, Texas
Trial Court Cause No. DC-18-05781
MEMORANDUM OPINION
Before Justices Bridges, Molberg, and Carlyle Opinion by Justice Carlyle Physician Mary Caire appeals the trial court’s judgment confirming an
arbitration award in favor of appellee Genetic Direction, LLC. In two issues, Ms. Caire contends the trial court erred by granting Genetic Direction’s motion to compel arbitration and by confirming the arbitration award. We affirm in this memorandum opinion. See TEX. R. APP. P. 47.7. Background In November 2014, Ms. Caire and Genetic Direction signed a written “Professional Services Agreement” (PSA) in which Genetic Direction retained Ms.
Caire “as its Medical Director and to provide professional medical and consultative services.” The PSA stated (1) in consideration for Ms. Caire “performing duties requisite to launching the Company and its services,” Genetic Direction “shall grant Physician 2% (two percent) membership interest in the Company (the ‘Sign-On Consideration’), vesting according to the following schedule: 1.0% - Upon Execution of this Agreement; 0.5% - December 31, 2015; 0.5% - December 31, 2016,” and (2) in consideration for Ms. Caire “providing the Professional Services,” Genetic Direction “shall pay Physician $2,000 per month” and she will “accrue an additional $2,000 per month in deferred compensation” payable at the company’s discretion, which “will remain payable to Physician” in the event of the PSA’s termination. Either party could terminate the PSA “at any time and for any reason.” The PSA also contained an arbitration provision that stated “any unresolved dispute or controversy arising under or in connection with the Agreement shall be settled exclusively by arbitration.”
In December 2014, Ms. Caire and Genetic Direction signed a written “Buy-
Sell Agreement” (BSA), which (1) described restrictions and procedures applicable to any sale or transfer of owners’ interests in Genetic Direction and (2) provided, among other things, a formula for determining the minimum price at which an owner or the company was entitled to purchase the interest of an owner who “ceases to be an employee of the Company” or is otherwise “deemed to have offered to sell such Owner’s Interests.” The BSA also stated, “This Agreement constitutes the entire
agreement of the Owners among themselves or with the Company regarding the subject matter of this Agreement and supersedes all prior agreements regarding such subject matter.” The BSA did not include an arbitration clause.
Ms. Caire terminated the PSA in January 2015. One month later, Genetic Direction sent Ms. Caire a letter stating that pursuant to the BSA, the company was “exercising its right to purchase your 1% membership interest” for the price provided for in the BSA, which the company had determined was $27.25. A cashier’s check for that amount was enclosed.
In March 2018, Ms. Caire sent Genetic Direction a letter demanding (1) the “remaining 1%” of the 2% interest she “was to be compensated by” under the PSA; (2) $11,066.66 in unpaid compensation for November 2014 through January 2015; and (3) documentation to substantiate the claimed $27.25 valuation of her 1% ownership interest the company had sought to buy back.
Genetic Direction served Ms. Caire with an April 12, 2018 demand for arbitration and “Statement of Claim.” Genetic Direction (1) contended Ms. Caire “breached the PSA by failing to perform the required services” and (2) sought a declaration that “as a result of Ms. Caire’s termination of the PSA and, prior to such termination, her failure to perform services under the PSA, Ms. Caire is not entitled to the claimed 2% ownership interests or compensation.”
Ms. Caire filed a May 2, 2018 petition in the trial court. She contended that “in consideration for performing duties requisite to the launching of the company
and its services,” she “was provided a 2% interest in ownership” of Genetic Direction “pursuant to the terms of the PSA.” She asserted a claim for breach of the BSA and sought a declaratory judgment that she currently held a “vested 2% ownership interest” in Genetic Direction because the company “never complied with the requisite provisions of the [BSA]” regarding the purchase of her interest.
Genetic Direction moved to compel arbitration, asserting that the vesting of ownership interests was dependent on Ms. Caire providing the services described in the PSA and “[p]rior to her termination of the PSA, Ms. Caire had failed to provide services as required.” Genetic Direction stated that because Ms. Caire’s claims “relate to [her] alleged ownership interests including what equity interest, if any, vested” and “are tied to her provision of services and the granting of ownership interests, which are governed by the PSA,” her claims “fall within the scope of the arbitration agreement signed by the parties and must be brought in arbitration.”
Ms. Caire filed a response to the motion to compel in which she contended (1) she “is the owner of 2% of Defendant pursuant to the terms of the PSA”; (2) the BSA “specifies that [the BSA] was the entire agreement of the Owners and superseded any prior written agreements”; and (3) “[t]he [BSA] has NO provisions which allow for Arbitration.”
Ms. Caire’s counsel did not appear at the hearing on the motion to compel arbitration, and the trial court signed a June 18, 2018 order granting that motion. Ms. Caire moved for reconsideration, asserting counsel’s failure to appear “was due to
accident or mistake,” and contended “good cause exist[s] for the reconsideration of the motion,” restating her arguments described above. The trial court denied reconsideration, and arbitration proceeded.
The arbitrator signed a December 17, 2018 award in Genetic Direction’s favor, stating Ms. Caire “is not entitled to any membership interests in Genetic Direction, LLC” and awarding Genetic Direction $40,000.00 in attorney’s fees plus the arbitration fees and expenses. In late December 2018, Genetic Direction moved to confirm the arbitration award.
Ms. Caire filed a January 3, 2019 motion to vacate the award pursuant to Texas Civil Practice and Remedies Code section 171.088(a)(4), which requires a court to vacate an award if “there was no agreement to arbitrate, the issue was not adversely determined in a proceeding under Subchapter B, and the party did not participate in the arbitration hearing without raising the objection.” In its response, Genetic Direction asserted that Ms. Caire “fails” two of section 171.088(a)(4)’s three requirements because “[t]here was an agreement to arbitrate” and “[t]he issue of arbitrability was adversely determined by [the trial court].”
After a hearing, the trial court denied Ms. Caire’s motion to vacate the arbitration award and granted Genetic Direction’s motion to confirm the award. The trial court did not abuse its discretion by compelling arbitration We review a trial court’s order granting or denying a motion to compel arbitration for abuse of discretion, deferring to the trial court’s factual determinations
if they are supported by evidence but reviewing its legal determinations de novo. In re Labatt Food Serv., L.P., 279 S.W.3d 640, 642–43 (Tex. 2009). Whether the claims in dispute fall within the scope of a valid arbitration agreement is a question of law and thus is reviewed de novo. Id.; see also Perry Homes v. Cull, 258 S.W.3d 580, 585–87 (Tex. 2008) (concluding appellate courts may review trial court orders compelling arbitration on appeal from final judgment rendered upon confirmation of arbitration award).
Free access — add to your briefcase to read the full text and ask questions with AI
Mary Caire v. Genetic Direction LLC (Mary Caire v. Genetic Direction LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.